FDA grants breakthrough therapy designation to Daiichi Sankyo’s FLT3 inhibitor quizartinib for relapsed/refractory FLT3-ITD AML

Daiichi Sankyo

1 August 2018 - Third breakthrough therapy designation granted by FDA for a compound in the oncology pipeline of Daiichi Sankyo, reinforcing the company’s commitment to transforming science into value for patients with cancer.

Daiichi Sankyo has announced that the U.S.FDA has granted breakthrough therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukaemia.

The designation was granted based on the results of the QuaNTUM-R trial which were presented during the plenary program at the 23rd Congress of the European Hematology Association in June 2018.

Read Daiichi Sankyo press release

Michael Wonder

Posted by:

Michael Wonder